Moleculin Biotech, Inc. (MBRX)
0.77
+0.02
(+2.65%)
USD |
NASDAQ |
Sep 09, 14:01
Moleculin Biotech Debt to Equity Ratio : 0.0252 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0252 |
| March 31, 2026 | 0.0215 |
| December 31, 2025 | 0.0239 |
| September 30, 2025 | -0.0145 |
| June 30, 2025 | -0.0586 |
| March 31, 2025 | 10.71 |
| December 31, 2024 | 0.0426 |
| September 30, 2024 | 0.0426 |
| June 30, 2024 | 0.03 |
| March 31, 2024 | 0.0259 |
| December 31, 2023 | 0.022 |
| September 30, 2023 | 0.0166 |
| June 30, 2023 | 0.0072 |
| March 31, 2023 | 0.0067 |
| December 31, 2022 | 0.0086 |
| September 30, 2022 | 0.0082 |
| June 30, 2022 | 0.0073 |
| March 31, 2022 | 0.0017 |
| December 31, 2021 | 0.002 |
| September 30, 2021 | 0.0023 |
| June 30, 2021 | 0.0026 |
| March 31, 2021 | 0.0028 |
| Date | Value |
|---|---|
| December 31, 2020 | 0.0155 |
| September 30, 2020 | 0.021 |
| June 30, 2020 | 0.0211 |
| March 31, 2020 | 0.0232 |
| December 31, 2019 | 0.0243 |
| September 30, 2019 | 0.0213 |
| June 30, 2019 | 0.0093 |
| March 31, 2019 | 0.0145 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.0067 |
| December 31, 2016 | 0.0198 |
| September 30, 2016 | 0.0183 |
| June 30, 2016 | 0.0247 |
| March 31, 2016 | -0.8974 |
| December 31, 2015 | -0.6067 |
| September 30, 2015 | -1.102 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 21.09M |
| Total Liabilities (Quarterly) | 9.50M |
| Shareholders Equity (Quarterly) | 11.59M |
| Current Ratio | 0.9366 |
| Net Debt Paydown Yield | 0.16% |